Status:
NOT_YET_RECRUITING
A Clinical Study on LM103 Injection for the Treatment of Advanced Solid Tumors
Lead Sponsor:
Suzhou BlueHorse Therapeutics Co., Ltd.
Conditions:
Solid Tumor
Eligibility:
All Genders
18-75 years
Phase:
EARLY_PHASE1
Brief Summary
This study is an open exploratory clinical study to evaluate the safety, tolerance, immune response, and initial efficacy of autologous tumor infiltrating lymphocyte LM103 injection in advanced solid ...
Eligibility Criteria
Inclusion
- The expected survival time is not less than 6 months.
- Clinical performance status of Eastern Cooperative Oncology Group (ECOG) 0-1.
- Patients with advanced solid tumors confirmed by histology or cytology: advanced Melanoma, head and neck squamous cell cancer, soft tissue sarcoma and other solid tumors that have failed standard treatment regimens, cannot tolerate standard treatment, refuse or do not have standard treatment regimens available.
- The patient has lesions that can be used for surgical resection (\>1.5 cm\^3) or biopsy puncture (no less than 6 lesions) for TILs collection.
- At least one measurable lesion as the target lesion after collecting tumor tissue from the patient (RECIST v1.1 criteria).
- Laboratory tests results during the screening period indicate that the subjects have sufficient organ function.
Exclusion
- Have a medical history of other malignant tumors other than the disease under study in the past 5 years, except for malignant tumors that can be expected to recover after treatment (including but not limited to thyroid cancer, cervical Carcinoma in situ, basal or squamous cell skin cancer or Ductal carcinoma in situ of the breast treated by radical surgery).
- LM103 received systematic Sex therapy of antineoplastic drugs (including chemotherapy, small molecule targeted drug therapy, Hormone replacement therapy, etc.), or local antineoplastic therapy (such as radiotherapy, palliative radiotherapy for bone metastases\>2 weeks before the start of the study and intracranial stereotactic radiotherapy or resection of a single brain metastasis\>3 weeks before the start of the study were acceptable) within 4 weeks before LM103 infusion; Or received clinical investigational drugs or equipment treatment.
- Adverse reactions caused by previous treatment have not recovered to CTCAE (version 5.0) level 1 or below (excluding hair loss and neurotoxicity, which have been determined by the researchers to be irreparable and level 2 hypothyroidism for a long time).
- Previously received allogeneic hematopoietic stem cell transplantation or solid organ transplantation.
Key Trial Info
Start Date :
August 1 2023
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
August 1 2026
Estimated Enrollment :
5 Patients enrolled
Trial Details
Trial ID
NCT05971589
Start Date
August 1 2023
End Date
August 1 2026
Last Update
August 2 2023
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.